A pharmaceutical company in China said that the vaccine against the new coronavirus that it is developing should be ready in early 2021 for distribution worldwide, including in Europe and the United States.
Yin Weidong, the CEO of SinoVac, said he personally received the experimental vaccine.
“At the beginning, our strategy was designed for China and Wuhan, but in June and July, we adjusted to cover the whole world,” he revealed.
“Our goal now is to supply the vaccine to everyone, including the United States, the European Union and others,” said Yin.
Strict regulations in the US, the European Union, Japan and Australia have historically blocked the sale of Chinese vaccines, but Yin said that could change.
SinoVac is developing one of four vaccine candidates in China, along with state-owned SinoPharm, which has two others under development, and the private company affiliated with the Chinese army CanSino.
More than 24,000 people are participating in clinical trials conducted by CoronaVac in Brazil, Turkey and Indonesia, said Yin.
Read more in Diário de Notícias
This article is available in: Português